HAE•Haemonetics said the FDA approved PerQseal Elite, a device that seals arterial openings after minimally invasive heart and vascular procedures. Approval covers use with large access sheaths commonly used in structural heart and endovascular procedures.
Haemonetics said the FDA approved PerQseal Elite, which uses a fully absorbable patch that dissolves over time and does not leave a permanent implant. Physicians can check whether bleeding has stopped while retaining guidewire access during the procedure, the company said.
Haemonetics obtained the technology through its January 2026 acquisition of Ireland-based Vivasure Medical. The company plans to present additional clinical data at the Transcatheter Cardiovascular Therapeutics conference later this month.
